Anti-tumor properties of lymphocytes activated by the oxidizing mitogens.
Human peripheral blood mononuclear cells when activated with the oxidizing mitogens, neuraminidase/galactose oxidase or sodium periodate, express cytolytic activity for freshly isolated tumor cells and for a variety of cell lines, including NK-resistant solid tumor lines. Normal lymphoid cells are not targets for cytotoxicity and do not inhibit lysis of susceptible targets mediated by the oxidizing mitogen-activated mononuclear cells. The cytotoxic response is rapidly generated and reaches peak levels at 48 hr. The oxidizing mitogens induce expression of IL 2 receptors on peripheral blood mononuclear cells. Combined treatment of cells with IL 2 and the oxidizing mitogens results in a marked enhancement of cytotoxicity. Enhancement is achieved at levels of IL 2 that alone result in minimal generation of cytotoxic cells. Growth of a human renal cancer cell line in nude mice was inhibited when the renal cancer cells were injected together with oxidizing mitogen-activated human mononuclear cells. These studies indicate that oxidizing mitogen-activated cells provide a potentially valuable source of material for the adoptive immunotherapy of tumors.
D000276:Adjuvants, Immunologic / Q000502:physiology; D000328:Adult; D000818:Animals; D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy; D002455:Cell Division; D003601:Cytotoxicity Tests, Immunologic; D003602:Cytotoxicity, Immunologic; D005260:Female; D005692:Galactose Oxidase / Q000494:pharmacology*; D006801:Humans; D007376:Interleukin-2 / Q000502:physiology; D007680:Kidney Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy; D008213:Lymphocyte Activation; D051379:Mice; D008819:Mice, Nude; D009439:Neuraminidase / Q000494:pharmacology*; D010504:Periodic Acid / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D007376:Interleukin-2; D010504:Periodic Acid; C009288:metaperiodate; D005692:Galactose Oxidase; D009439:Neuraminidase